BACKGROUND: Carvedilol treatment reduces the mortality rate in patients with congestive heart failure. It is not known whether carvedilol treatment is effective in heart failure patients with substantial cardiac sympathetic nerve dysfunction. The goal of this study was to determine the effect of chronic carvedilol treatment in patients with cardiac sympathetic nerve dysfunction of varying severity. METHODS AND RESULTS: In 22 congestive heart failure patients with idiopathic cardiomyopathy, sympathetic nerve function was assessed before and after 7.2 +/- 2.7 months of carvedilol treatment with the use of iodine 123 metaiodobenzylguanidine (MIBG) imaging, radionuclide ventriculography, and transmyocardial norepinephrine sampling. Patients with relatively advanced impairment of cardiac sympathetic nerve function, as manifested by a baseline I-123 MIBG ratio lower than 1.40, had a statistically significant improvement in I-123 heart-mediastinum ratio with carvedilol treatment, from 1.26 +/- 0.12 to 1.39 +/- 0.20 (P =.004). Of 10 patients with a baseline I-123 MIBG ratio lower than 1.40, 9 had an increase in the heart-mediastinum ratio with carvedilol treatment. Left ventricular ejection fraction increased from 25.4% +/- 7.8% to 37.3% +/- 14.7% (P <.001), with no difference between patients with relatively advanced versus relatively preserved cardiac sympathetic nerve function. CONCLUSION: Most patients with congestive heart failure show a favorable response in left ventricular function to carvedilol treatment, regardless of the baseline level of cardiac sympathetic nervous system function, as assessed by neuronal imaging with I-123 MIBG. Patients with relatively advanced impairment of baseline I-123 MIBG uptake are most likely to show evidence of improved cardiac sympathetic nervous system function in response to carvedilol therapy.
BACKGROUND:Carvedilol treatment reduces the mortality rate in patients with congestive heart failure. It is not known whether carvedilol treatment is effective in heart failurepatients with substantial cardiac sympathetic nerve dysfunction. The goal of this study was to determine the effect of chronic carvedilol treatment in patients with cardiac sympathetic nerve dysfunction of varying severity. METHODS AND RESULTS: In 22 congestive heart failurepatients with idiopathic cardiomyopathy, sympathetic nerve function was assessed before and after 7.2 +/- 2.7 months of carvedilol treatment with the use of iodine 123 metaiodobenzylguanidine (MIBG) imaging, radionuclide ventriculography, and transmyocardial norepinephrine sampling. Patients with relatively advanced impairment of cardiac sympathetic nerve function, as manifested by a baseline I-123MIBG ratio lower than 1.40, had a statistically significant improvement in I-123 heart-mediastinum ratio with carvedilol treatment, from 1.26 +/- 0.12 to 1.39 +/- 0.20 (P =.004). Of 10 patients with a baseline I-123MIBG ratio lower than 1.40, 9 had an increase in the heart-mediastinum ratio with carvedilol treatment. Left ventricular ejection fraction increased from 25.4% +/- 7.8% to 37.3% +/- 14.7% (P <.001), with no difference between patients with relatively advanced versus relatively preserved cardiac sympathetic nerve function. CONCLUSION: Most patients with congestive heart failure show a favorable response in left ventricular function to carvedilol treatment, regardless of the baseline level of cardiac sympathetic nervous system function, as assessed by neuronal imaging with I-123MIBG. Patients with relatively advanced impairment of baseline I-123MIBG uptake are most likely to show evidence of improved cardiac sympathetic nervous system function in response to carvedilol therapy.
Authors: P Merlet; C Benvenuti; D Moyse; F Pouillart; J L Dubois-Randé; A M Duval; D Loisance; A Castaigne; A Syrota Journal: J Nucl Med Date: 1999-06 Impact factor: 10.057
Authors: L E Wagoner; L L Craft; B Singh; D P Suresh; P W Zengel; N McGuire; W T Abraham; T C Chenier; G W Dorn; S B Liggett Journal: Circ Res Date: 2000-04-28 Impact factor: 17.367
Authors: E M Gilbert; W T Abraham; S Olsen; B Hattler; M White; P Mealy; P Larrabee; M R Bristow Journal: Circulation Date: 1996-12-01 Impact factor: 29.690
Authors: J C Sisson; B Shapiro; L Meyers; S Mallette; T J Mangner; D M Wieland; J V Glowniak; P Sherman; W H Beierwaltes Journal: J Nucl Med Date: 1987-10 Impact factor: 10.057
Authors: S B Liggett; L E Wagoner; L L Craft; R W Hornung; B D Hoit; T C McIntosh; R A Walsh Journal: J Clin Invest Date: 1998-10-15 Impact factor: 14.808
Authors: M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman Journal: N Engl J Med Date: 1996-05-23 Impact factor: 91.245
Authors: Hein J Verberne; Christel Feenstra; W Matthijs de Jong; G Aernout Somsen; Berthe L F van Eck-Smit; Ellinor Busemann Sokole Journal: Eur J Nucl Med Mol Imaging Date: 2005-05-18 Impact factor: 9.236
Authors: Peter Hanna; Pradeep S Rajendran; Olujimi A Ajijola; Marmar Vaseghi; J Andrew Armour; Jefrrey L Ardell; Kalyanam Shivkumar Journal: Auton Neurosci Date: 2017-07-29 Impact factor: 3.145